Parameter | All patients diagnosed with stage IIIB–IV NSCLC (2012–2016) | Patients diagnosed with stage IIIB–IV NSCLC in 2012–2014 (no treatment data available) | Patients diagnosed with stage IIIB–IV NSCLC in 2015–2016 (treatment data available) | P valuea |
---|---|---|---|---|
All N = 1008 | All N = 616 | All N = 392 | ||
Median age (IQR), years | 65 (58–73) | 66 (58–74) | 65 (57–72) | |
Age range | 21–92 | 21–92 | 27–90 | |
Age at diagnosis in years, n (%) | 0.854 | |||
< 65 | 478 (47.4) | 288 (46.8) | 190 (48.5) | |
65–74 | 307 (30.5) | 189 (30.7) | 118 (30.1) | |
≥ 75 | 223 (22.1) | 139 (22.6) | 84 (21.4) | |
Sex, n (%) | 0.316 | |||
Male | 762 (75.6) | 459 (74.5) | 303 (77.3) | |
Female | 246 (24.4) | 157 (25.5) | 89 (22.7) | |
TNM stage, n (%) | 0.290 | |||
IIIB | 154 (15.3) | 100 (16.2) | 54 (13.8) | |
IV | 854 (84.7) | 516 (83.8) | 338 (86.2) | |
Histology, n (%) | 0.043 | |||
NSQ | 720 (71.4) | 431 (70.0) | 289 (73.7) | |
Adenocarcinoma | 713 (70.7) | 429 (69.6) | 284 (72.4) | |
SQ | 210 (20.8) | 127 (20.6) | 83 (21.2) | |
NSCLC NOS | 57 (5.7) | 45 (7.3) | 12 (3.1) | |
Other histologies | 21 (2.1) | 13 (2.1) | 8 (2.0) |